How do different treatments for amyotrophic lateral sclerosis compare when looking at many trials together?
When comparing treatments for amyotrophic lateral sclerosis (ALS) across many trials, the evidence points to a few approaches that may help slow the disease. A large network meta-analysis of 109 randomized controlled trials found that the combination of cell therapy and neuroprotective agents showed the greatest effect on slowing functional decline, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) 3. Non-pharmacological treatments like exercise and respiratory interventions also showed benefits 9. However, many individual drug trials have been disappointing, and no single treatment works for everyone.
What the research says
A 2025 network meta-analysis pooled data from 109 trials involving over 16,000 people with ALS 3. It compared various pharmacological and biological therapies. The combination of cell therapy and neuroprotective agents was ranked highest for slowing decline on the ALSFRS-R scale, with a mean difference of 3.65 points compared to placebo 3. This is a meaningful difference, as the ALSFRS-R measures abilities like speaking, walking, and breathing.
Non-pharmacological treatments also show promise. A 2024 network meta-analysis of five types of interventions (exercise, nutrition, respiratory, psychological, and integrated physical interventions) found that exercise had beneficial effects on functional status, muscle strength, quality of life, and lung function 9. Respiratory interventions also improved functional scores 9. A separate 2021 trial found that a 12-week program of combined aerobic and strength training improved respiratory function, mobility, and ALSFRS-R scores compared to stretching alone 10.
Not all treatments have succeeded. A large trial of reldesemtiv, a drug that targets muscle function, was stopped early because it did not show benefit 4. The drug did not affect the need for durable medical equipment like wheelchairs or ventilators 4. Another analysis of pooled trial data using a new method called entropy analysis suggested that active treatments may delay functional decline in certain domains, but this finding needs confirmation 5.
Some treatments have shown promise in specific analyses. A post-hoc analysis of masitinib, a drug that targets immune cells in the brain, found that 42.3% of patients taking 4.5 mg/kg/day survived at least 5 years from symptom onset, compared to predicted survival rates 7. However, this was not from a primary trial analysis, so the results should be interpreted cautiously.
What to ask your doctor
- What does the research say about combining cell therapy with neuroprotective agents for ALS? Is this available or still experimental?
- Would a structured exercise program, including aerobic and strength training, be safe and appropriate for my current stage of ALS?
- Are there any ongoing clinical trials for new ALS treatments that I might be eligible for?
- How can I monitor my respiratory function, and what are the benefits of early respiratory interventions?
- What is your opinion on the potential of masitinib or similar drugs based on the latest evidence?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.